Contact
Please use this form to send email to PR contact of this press release:
FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
TO:
Please use this form to send email to PR contact of this press release:
FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
TO: